Answers are grounded in this paper and cite their sources.
The hybrid tumor vaccine improves immune activation in cancer, suggesting enhanced clinical efficacy.
Preventive tumor vaccines exhibit substantial potential in averting tumorigenesis; nevertheless, their clinical efficacy remains constrained by challenges in eliciting potent and long-lasting immune activation, which ultimately leads to subpar overall...
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: